What is Digestive Care?
Digestive Care, Inc. is a pharmaceutical company focused on addressing exocrine pancreatic insufficiency (EPI) through its prescription medication, PERTZYE. Available in multiple lipase unit strengths, PERTZYE is engineered to aid individuals experiencing difficulties with normal food digestion due to inadequate pancreatic enzyme production. The company extends its support through patient assistance programs, including co-pay aid and nutritional guidance, targeting patients with EPI, cystic fibrosis, pancreatitis, and pancreatic cancer.
How much funding has Digestive Care raised?
Digestive Care has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Digestive Care
PPP
Public-Private Partnership
What's next for Digestive Care?
The substantial late-stage funding and recent strategic investment signal a pivotal moment for Digestive Care, Inc. This capital infusion is likely earmarked for expanding market reach, enhancing manufacturing capabilities, and potentially advancing its product pipeline. The company's focus on a critical unmet medical need in digestive health positions it for continued growth and market leadership in specialized pharmaceutical treatments.
See full Digestive Care company page
